SEC targets ArthroCare
This article was originally published in The Gray Sheet
Executive Summary
Bank of America Equity Research analyst Steven Lichtman tells investors Aug. 24 that his group found "no unusual patterns in the timing or pricing of options and no evidence of backdating" in its review of ArthroCare documents. The previous day, the U.S. Securities & Exchange Commission asked to review information about ArthroCare's stock option grant practices. "We see no reason at this point to believe that filing delays or financial restatements are imminent," Lichtman wrote in a research brief...